文献速递妇科

综合基因组谱分析揭示卵巢高钙血症型小细胞癌中SMARCA4失活突变及低肿瘤突变负荷

Comprehensive genomic profiling reveals inactivating SMARCA4 mutations and low tumor mutational burden in small cell carcinoma of the ovary, hypercalcemic-type.
PubMed 文献 · Gynecol Oncol · 2017-11-06

该研究对18例卵巢高钙血症型小细胞癌(SCCOHT)行综合基因组谱分析(CGP),其中16例经典型形态者94%(15/16)存在SMARCA4失活突变且肿瘤突变负荷(TMB)低(<6个突变/Mb)。2例仅大细胞变异形态者均为SMARCA4野生型且高突变(TMB分别为90和360个突变/Mb)。回顾性数据库搜索另发现3例原诊断非SCCOHT的晚期卵巢肿瘤具有类似基因组特征,其中1例原诊断为子宫内膜样癌者被重新分类为SCCOHT并对SCCOHT化疗方案有应答。

要点

  • 经典型SCCOHT中94%(15/16)存在SMARCA4失活突变且TMB低(<6个突变/Mb)。
  • 仅大细胞变异形态的2例均为SMARCA4野生型且高突变(TMB 90和360个突变/Mb)。
  • CGP有助于SCCOHT及组织学/临床特征重叠病变的诊断与治疗决策。

核心结论

  • 绝大多数SCCOHT存在基因组SMARCA4缺失,仅少数伴其他基因改变。
  • 数据支持CGP用于SCCOHT及组织学与临床特征重叠病变的诊断和管理,因通过基因组谱识别前者提示可从合适方案和治疗决策中获益,如示例患者所示。

研究设计与样本

  • 对18例SCCOHT(16例经典型形态,2例仅大细胞变异形态)行CGP,评估最多406个癌症常见突变基因的全部编码改变及最多31个癌症常见重排基因的内含子区域。
  • 回顾性数据库搜索具有与SCCOHT相似基因组谱的晚期卵巢肿瘤,另发现3例原诊断为非SCCOHT的病例。

主要发现

  • 经典型形态SCCOHT中94%(15/16)存在SMARCA4失活改变且TMB低(<6个突变/Mb)。
  • 仅大细胞变异形态的2例(2/2)均为高突变(TMB分别为90和360个突变/Mb)且SMARCA4野生型。
  • 回顾性搜索中1例原诊断为子宫内膜样癌的卵巢癌患者携带SMARCA4失活改变,被重新分类为SCCOHT并对SCCOHT化疗方案有应答。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Small cell carcinoma of the ovary, hypercalcemic-type (SCCOHT) is a rare, extremely aggressive neoplasm that usually occurs in young women and is characterized by deleterious germline or somatic SMARCA4 mutations. We performed comprehensive genomic profiling (CGP) to potentially identify additional clinically and pathophysiologically relevant genomic alterations in SCCOHT. METHODS: CGP assessment of all classes of coding alterations in up to 406 genes commonly altered in cancer and intronic regions for up to 31 genes commonly rearranged in cancer was performed on 18 SCCOHT cases (16 exhibiting classic morphology and 2 cases exhibiting exclusive a large cell variant morphology). In addition, a retrospective database search for clinically advanced ovarian tumors with genomic profiles similar to SCCOHT yielded 3 additional cases originally diagnosed as non-SCCOHT. RESULTS: CGP revealed inactivating SMARCA4 alterations and low tumor mutational burden (TMB) (<6mutations/Mb) in 94% (15/16) of SCCOHT with classic morphology. In contrast, both (2/2) cases exhibiting only large cell variant morphology were hypermutated (TMB scores of 90 and 360mut/Mb) and were wildtype for SMARCA4. In our retrospective search, an index ovarian cancer patient harboring inactivating SMARCA4 alterations, initially diagnosed as endometrioid carcinoma, was re-classified as SCCOHT and responded to an SCCOHT chemotherapy regimen. CONCLUSION: The vast majority of SCCOHT demonstrate genomic SMARCA4 loss with only rare co-occurring alterations. Our data support a role for CGP in the diagnosis and management of SCCOHT and of other lesions with overlapping histological and clinical features, since identifying the former by genomic profile suggests benefit from an appropriate regimen and treatment decisions, as illustrated by an index patient.

来源:Gynecol Oncol,查看原文。版权归原作者所有。

引用

  1. Lin DI, Chudnovsky Y, Duggan B, et al. Comprehensive genomic profiling reveals inactivating SMARCA4 mutations and low tumor mutational burden in small cell carcinoma of the ovary, hypercalcemic-type. Gynecol Oncol. 2017. PMID: 29102090. doi:10.1016/j.ygyno.2017.09.031

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。